Quick Win by the Algorithm: Nektar Therapeutics (NASDAQ: NKTR) Treats Investors With Stock Up 383.54% In 1 Year
Quick Algorithm
“This past year was truly transformational for Nektar as we achieved a number of successes with Nektar medicines across our three key therapeutic areas of immuno-oncology, immunology and pain”
– Howard W. Robin, President and Chief Executive Officer of Nektar Therapeutics
(Image Source: Nektar)
Over the past year Nektar Therapeutic’s stock price steadily grew from $21.60 to $104.51 per share, outperforming the market by more than 365%. So what is the driver behind that growth and what happened during 2017 financial year? The reason lies in the company’s results